Anecdotally, some physicians are getting more comfortable prescribing compounded versions of popular weight loss drugs Wegovy and Zepound, which are both in short supply, NBC News reported Aug. 16.
Lykos Therapeutics, the manufacturer of midomafetamine (MDMA), which had been tested for PTSD treatment, will reduce its workforce by 75% after the FDA rejected the company's new drug application.
Some patients are dose splitting their GLP-1 injection pens as they struggle to pay thousands of dollars for the diabetes and weight loss medications, The Atlantic reported Aug. 15.
About two-thirds of providers recently told Premier their teams are spending more than 10 hours per week mitigating supply chain challenges and shortages.
Drug manufacturer Eli Lilly & Co. has sent cease-and-desist letters to U.S. healthcare providers demanding an end to the promotion and sale of copycat versions of the company's Mounjaro and Zepbound GLP-1 drugs, Bloomberg reported Aug. 15.
The largest buyer of pharmaceuticals in the U.S. — Medicare, which covered more than 67 million people as of April — has bargaining power in an industry worth $640 billion.
Mail-order pharmacies run well-coordinated supply chain operations to ensure medications are safely delivered to patients' doorsteps, but extreme temperatures are complicating the process, The New York Times reported Aug. 13.
